Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outpatient Parenteral Antimicrobial Therapy in Asia: Evolution, Models, and Challenges over the Past Decade-A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundUnplanned healthcare utilization events, including hospital readmissions and emergency room visits, are common in patients receiving outpatient parenteral antimicrobial therapy (OPAT). Little is known about patient adherence to therapy in this setting. This clinical trial evaluates the impact of a remote therapeutic monitoring (RTM) device with an integrated care platform on all-cause healthcare utilization in patients on OPAT.
methodsThis prospective, open-label, nonrandomized study enrolled patients discharged on OPAT to receive the IV Ensure RTM device compared to contemporaneous controls. The primary outcome was all-cause healthcare utilization, including hospital readmission or emergency room visit, assessed at day 90 after discharge. Adherence to antimicrobial therapy was evaluated in the intervention group.
resultsA total of 81 patients were enrolled in the intervention group, with 131 patients in the control group. Both groups had similar baseline and OPAT characteristics. On multivariate Cox regression analysis, the RTM intervention was associated with a 39% reduction in all-cause healthcare utilization by day 60 (adjusted hazard ratio, 0.61 [95% confidence interval, .38-.96]; P = .03]) and a 38% reduction by day 90 (0.62 [.40-.95]; P = .03). In the intervention group, the overall adherence reached a median of 94%, and 61.7% of patients maintained adherence of >90% throughout their OPAT course.
conclusionsAn RTM device with an integrated care platform significantly reduced all-cause healthcare utilization events in patients on OPAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.